As of 2026-02-18, the EV/EBITDA ratio of Medincell SA (MEDCL.PA) is -122.58. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MEDCL.PA's latest enterprise value is 871.27 mil EUR. MEDCL.PA's TTM EBITDA according to its financial statements is -7.11 mil EUR. Dividing these 2 quantities gives us the above MEDCL.PA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 3.7x - 6.0x | 4.8x |
| Forward P/E multiples | 10.8x - 11.8x | 11.3x |
| Fair Price | (4.08) - (3.05) | (3.49) |
| Upside | -116.6% - -112.4% | -114.2% |
| Date | EV/EBITDA |
| 2026-02-16 | -120.99 |
| 2026-02-13 | -124.81 |
| 2026-02-12 | -121.18 |
| 2026-02-11 | -120.62 |
| 2026-02-10 | -117.36 |
| 2026-02-09 | -121.55 |
| 2026-02-06 | -118.94 |
| 2026-02-05 | -116.89 |
| 2026-02-04 | -115.21 |
| 2026-02-03 | -115.86 |
| 2026-02-02 | -116.24 |
| 2026-01-30 | -113.35 |
| 2026-01-29 | -115.77 |
| 2026-01-28 | -120.15 |
| 2026-01-27 | -137.58 |
| 2026-01-26 | -131.15 |
| 2026-01-23 | -144.30 |
| 2026-01-22 | -142.15 |
| 2026-01-21 | -137.49 |
| 2026-01-20 | -134.32 |
| 2026-01-19 | -135.44 |
| 2026-01-16 | -139.73 |
| 2026-01-15 | -133.48 |
| 2026-01-14 | -136.75 |
| 2026-01-13 | -131.06 |
| 2026-01-12 | -131.34 |
| 2026-01-09 | -126.96 |
| 2026-01-08 | -127.80 |
| 2026-01-07 | -127.98 |
| 2026-01-06 | -122.20 |
| 2026-01-05 | -119.59 |
| 2026-01-02 | -123.42 |
| 2025-12-31 | -125.65 |
| 2025-12-30 | -123.14 |
| 2025-12-29 | -124.72 |
| 2025-12-24 | -124.81 |
| 2025-12-23 | -123.88 |
| 2025-12-22 | -125.19 |
| 2025-12-19 | -125.56 |
| 2025-12-18 | -127.70 |
| 2025-12-17 | -128.26 |
| 2025-12-16 | -134.04 |
| 2025-12-15 | -133.02 |
| 2025-12-12 | -136.65 |
| 2025-12-11 | -144.11 |
| 2025-12-10 | -136.37 |
| 2025-12-09 | -131.62 |
| 2025-12-08 | -132.55 |
| 2025-12-05 | -129.38 |
| 2025-12-04 | -128.92 |